Sun Pharmaceutical Industries
India's largest drug company, which owns the branded cancer drugs Odomzo and Yonsa in the US and bought the PD-L1 antibody maker Checkpoint Therapeutics in 2025.
Overview
Sun Pharma was founded in 1983 by Dilip Shanghvi and is the fourth-largest specialty generics company in the world, with revenue of about 52,600 crore rupees in 2025. Its oncology strategy mixes generics (it was among the first US generic launchers of imatinib in 2016) with branded specialty products: it acquired Odomzo (sonidegib, for basal cell carcinoma) from Novartis in 2016, won FDA approval of Yonsa (a fine-particle abiraterone acetate) on 23 May 2018, and in 2025 acquired Checkpoint Therapeutics for about 355 million dollars, gaining the anti-PD-L1 antibody cosibelimab (Unloxcyt, FDA-approved for cutaneous squamous cell carcinoma in December 2024). In India it sells a broad oncology generics range.
Scorecard
All companies- approved products +30
- targets +8
- modalities +6
- regions +7
- 24-month regulatory events +2
- registry trials +30
Sonidegib (Odomzo) is the second hedgehog inhibitor for locally advanced basal cell carcinoma, similar in effect and side effects to vismodegib.
Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis.
Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice.
The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.
Aminolevulinic acid is painted on sun-damaged skin and then activated with a lamp, destroying actinic keratoses before they can become skin cancer; in Europe the gel is also approved for superficial basal cell carcinoma.
Pages like this
not linked directly; found by shared links- IdeaPublicly funded dose-reduction trials of expensive approved drugs
Shares Imatinib, Prices and value, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
- IdeaTransparent cost-plus pricing for every oral oncology generic
Shares Abiraterone acetate, Imatinib, Prices and value.
- CancerBasal cell carcinoma
Shares Aminolevulinic acid (topical, for photodynamic therapy), Sonidegib, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
- CompanyNatco Pharma
Shares Imatinib, Prices and value, Small-molecule kinase inhibitors.
- IdeaLimit secondary patents and pay-for-delay so cancer generics arrive on time
Shares Imatinib, Prices and value.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares PD-L1, Prices and value, Immune checkpoint inhibitors.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Imatinib, Prices and value.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Imatinib, Prices and value.